Abstract:Strategies to address the problem of poorly water-soluble drugs encompass the conversion of a crystalline drug into an amorphous form to promote its apparent solubility and dissolution. Co-amorphous systems (CAMs) incorporate low molecular mass molecules (co-formers), which are mixed with the drug to form one single phase [1 Blaabjerg LI, Lindenberg E, Rades T, et al. Influence of preparation pathway on the glass forming ability. Int J Pharm. 2017;521(1–2):232–239.[Crossref], [PubMed] , [Google Scholar],2 Dengale SJ, Grohganz H, Rades T, et al. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 2016;100:116–125.[Crossref], [PubMed], [Web of Science ®] , [Google Scholar]]. The aim of this study is to understand the capability of different co-formers (amino, carboxylic and sulphonic acids), in the production of CAMs with olanzapine by ball milling, solvent evaporation and quench cooling.Mixtures (2 g) of olanzapine (OLZ) and each co-former [l-aspartate (ASP); l-tryptophan (TRY); l-arginine (ARG); l-proline (PRO); citric acid (CIT); tartaric acid (TAR); oxalic acid (OXA); saccharine (SAC); potassium acessulfame (ACE); cyclamic acid (CYC)] in 1:1 molar ratios were submitted to ball milling (BM), solvent evaporation (SE) and quench cooling (QC). CAMs were evaluated for the OLZ solubility increase, co-formability and storage stability over time, by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD) and Fourier-transform infra-red spectroscopy (FTIR).The BM technique presented the most promising results followed by QC and SE (Table 1), since more CAMs were produced. All the sulphonic acids (SAC, CYC and ACE) formed CAMs regardless of the technique used, presenting complete amorphization probably due to their higher ability to produce intermolecular interactions, like hydrogen-bonding, thus increasing the stability of CAMs (more than 8 weeks at 25 °C/11 and 53% RH). Conversely, amino acids were the least efficient in producing CAMs. Crystalline OLZ presented low solubility (40.1 mg/L) in water and a general increase in the solubility of the CAMs was observed. Carboxylic acids (TAR, CIT, OXA) achieved the biggest increase (up to 269 times, BM with TART) followed by sulphonic acids (up to 199 times, SE with SAC), unveiling the possibility of improved dissolution profiles and bioavailability. Discussion and conclusions: The study has shown the possibility of converting a crystalline drug into an amorphous entity, particularly when in presence of co-formers which stabilise the amorphous structures formed. In fact, with sulphonic acids, both SE and BM, achieved complete amorphization and successfully stabilised the CAMs obtained. Due to the noteworthy increase in solubility, resulting from co-amorphization, this technique is considered to be adequate to process active compounds with poor water solubility, such as OLZ.Table 1. Comparison of the of co-amorphization ability using different techniques and co-formers.

Solid State Characterization of Azelnidipine–oxalic Acid Co-Crystal and Co-Amorphous Complexes: the Effect of Different Azelnidipine Polymorphs

Powder Grinding Preparation of Co-Amorphous Β-Azelnidipine and Maleic Acid Combination: Molecular Interactions and Physicochemical Properties

Azilsartan-nicotinamide cocrystal: Preparation, characterization and in vitro / vivo evaluation

Synthesis and structural characterization of two novel olanzapine cocrystals with decreased or enhanced dissolution rate

Pharmaceutical Cocrystals of Ethenzamide: Molecular Structure Analysis Based on Vibrational Spectra and DFT Calculations

The Comparative Study of Cocrystal/salt in Simultaneously Improving Solubility and Permeability of Acetazolamide

Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals

Polymorphs and Solvatomorphs of Azilsartan Medoxomil: Elucidation of Solvent-Induced Construction and Conformational Diversity

Design and Critical Characterization the Pharmaceutical Cocrystal of Azelnidipine With Coformers for Boosting Physicochemical Properties

Multicomponent Pharmaceutical Adducts of Azoxystrobin: Physicochemical Properties, Thermodynamic, and Molecular Modeling Study

Insight into the Structure and Property Diversity of Four Nicorandil Oxalate Salt Polymorphs Based on Experiments and Quantum Chemistry Study

Synthesis and Characterization of Nano-Sized 4-Aminosalicylic Acid-Sulfamethazine Cocrystals

Co-formability, solubility enhancement and stability of olanzapine co-amorphous systems produced with different co-formers

Crystallization Kinetics and Molecular Dynamics of Binary Coamorphous Systems of Nimesulide and Profen Analogs

Manipulation of Crystal Morphology of Zoxamide Based on Phase Diagram and Crystal Structure Analysis

Study on co-amorphous emerging solubilization behavior after gelation during dissolution: The importance of complexation and anti-crystallization

Selection of Bionic Co-former Improves the Dissolution of Neohesperidin via Co-amorphous Solid Dispersion with Naringin

Different Dissolution Molecular Pathways of Azilsartan Crystals with Different Forms Revealed by In Situ Atomic Force Microscopy

Poly (amino acid)s as new co-formers in amorphous solid dispersion

Investigation of the dissolution rate and oral bioavailability of atenolol-irbesartan co-amorphous systems

Polymorphic Forms of a Molecular Salt of Phenazopyridine with 3,5-Dihydroxybenzoic Acid: Crystal Structures, Theoretical Calculations, Thermodynamic Stability, and Solubility Aspects